Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Hyman Charles D

Hyman Charles D increased its position in Amgen Inc. (NASDAQ:AMGN) by 1.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 7,619 shares of the medical research company’s stock after purchasing an additional 105 shares during the period. Hyman Charles D’s holdings in Amgen were worth $2,381,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Bailard Inc. increased its stake in shares of Amgen by 0.4% during the second quarter. Bailard Inc. now owns 46,863 shares of the medical research company’s stock worth $14,642,000 after acquiring an additional 205 shares during the period. Verdence Capital Advisors LLC raised its stake in Amgen by 12.8% in the 2nd quarter. Verdence Capital Advisors LLC now owns 13,952 shares of the medical research company’s stock valued at $4,359,000 after purchasing an additional 1,588 shares during the last quarter. Catalyst Financial Partners LLC lifted its holdings in Amgen by 8.9% in the 2nd quarter. Catalyst Financial Partners LLC now owns 2,353 shares of the medical research company’s stock valued at $735,000 after purchasing an additional 193 shares in the last quarter. EFG Asset Management North America Corp. grew its holdings in shares of Amgen by 41.5% during the second quarter. EFG Asset Management North America Corp. now owns 4,287 shares of the medical research company’s stock worth $1,340,000 after buying an additional 1,258 shares in the last quarter. Finally, Townsend Asset Management Corp NC ADV raised its position in shares of Amgen by 5.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 1,510 shares of the medical research company’s stock valued at $472,000 after buying an additional 80 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 0.6 %

AMGN stock traded down $2.02 during mid-day trading on Monday, hitting $326.78. 1,769,856 shares of the company were exchanged, compared to its average volume of 2,577,947. The firm has a fifty day simple moving average of $323.17 and a 200 day simple moving average of $299.76. The company has a market capitalization of $175.30 billion, a PE ratio of 46.68, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58. Amgen Inc. has a twelve month low of $248.38 and a twelve month high of $346.85. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The firm’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter last year, the business posted $5.00 earnings per share. On average, research analysts forecast that Amgen Inc. will post 19.5 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.75%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio is currently 128.57%.

Analyst Ratings Changes

AMGN has been the subject of a number of recent analyst reports. Mizuho lifted their price objective on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Oppenheimer reaffirmed an “outperform” rating and set a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. Argus boosted their target price on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a report on Thursday, June 27th. TD Cowen upped their price target on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Eleven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $326.89.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.